Abstract
Targeting SHP2 phosphatase in Myeloproliferative Neoplasms
Highlights
Myeloproliferative neoplasms (MPNs) are clonal hematologic disorders which result in enhanced production of immature and mature myeloid lineagederived cells
While it is clear that Shp2 gain of function (GOF) mutations contribute to non-classical MPN; wildtype (WT) Shp2 is overexpressed and hyperactive in MPNs including in chronic myeloid leukemia (CML) and more recently in cells bearing an oncogenic form of KIT (KITD816V/KITD814V) associated with systemic mastocytosis (SM)[3]
Targeting Shp2 is likely to be of therapeutic benefit for treating juvenile myelomonocytic leukemia (JMML) and for diseases bearing an oncogenic form of KIT including SM
Summary
Myeloproliferative neoplasms (MPNs) are clonal hematologic disorders which result in enhanced production of immature and mature myeloid lineagederived cells. While it is clear that Shp2 gain of function (GOF) mutations contribute to non-classical MPN; wildtype (WT) Shp2 is overexpressed and hyperactive in MPNs including in chronic myeloid leukemia (CML) and more recently in cells bearing an oncogenic form of KIT (KITD816V/KITD814V) associated with SM[3].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
